Agilent Technologies, Inc. — Diagnostics & Research. Scored on the same transparent 7-signal model behind the daily rankings.
★
A
Agilent Technologies, Inc. · Diagnostics & Research
FCF$1.1bC+
Rev+9.1%B
D/E0.50B
P/E27.0xB
PEG1.14B+
70.3Score
$134.29$37.9B
1Y Target$159.21Analyst consensus · 19 analysts
5Y Target$233.10Compound horizon
10Y Target$345.79Long-dated conviction
FCF$1.1bTTMC+
FCF $1.1b — respectable but not differentiating
Rev+9.1%TTM YoYB
Revenue +9.1% — at or above S&P median
D/E0.50B
D/E 0.50 — near the Healthcare debt median (≈60th pctile)
P/E27.0xB
P/E 27.0 — near the Healthcare median (≈60th pctile)
PEG1.14B+
PEG 1.14 — near fair value, classic Lynch benchmark (1.0)
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 70.3
Quality0.73
Growth0.73
Value0.65
Entry · Margin of safety
52-week rangeMid-range
16% off the 12-month high
vs DCF fair value149% aboveest. fair value ~$54
What the price assumes: free cash flow compounding at ~30% a year for the next decade — vs the ~9% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability29% · Bgross profit ÷ total assets (Novy-Marx)
ROIC12.1% · B+return on invested capital — not score-weighted
Why now
Diagnostics & Research · market cap $37.9b. 16% off the 52-week high of $160.27. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $159.21 (implying +19% upside).
Moat
Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon
1-3 yr $159.21 (19-analyst consensus) — fundamentals + valuation re-rating. 5 yr $233.10 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $345.79 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · A
Trend
+2.9 over 15 daily scores
From 67.4 (Jun 22) → 70.3 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · A
$
%
%
Shares to buy
14
Position size
$1,880
3.8% of portfolio
Stop price
$100.72
25% below $134.29
$ at risk if stopped
$470.01
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Agilent Technologies, Inc. (A): score, valuation & FAQ
Agilent Technologies, Inc. (A) is a Diagnostics & Research company that scores 70.3 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are PEG (B+). On valuation, A sits about 149% above our discounted-cash-flow fair value — the current price implies roughly 30% annual free-cash-flow growth over the next decade.
Is A a good stock to buy?
Bull Rankings scores A 70.3 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by PEG (B+). A score is a quantitative screen of Agilent Technologies, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does A score 70.3 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). A earns its highest marks on PEG (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is A overvalued or undervalued?
Based on $134.29, A sits about 149% above our discounted-cash-flow fair value — the current price implies roughly 30% annual free-cash-flow growth over the next decade. It trades at a 27.0x× P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in A?
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.